Skip to content 
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's Disease; PMN267 for treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada. more
| Time Frame | PMN | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 11.5% | 0.72% | -1.31% |
| 1-Month Return | 99.63% | 1.27% | 0.78% |
| 3-Month Return | 81% | 3.13% | 3.46% |
| 6-Month Return | 5.1% | 15.81% | 6.19% |
| 1-Year Return | -27.6% | 8.89% | 11.68% |
| 3-Year Return | -86.7% | 20.79% | 71.21% |
| 5-Year Return | -90.13% | 35.89% | 74.81% |
| 10-Year Return | -72.85% | 138.44% | 256.59% |
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 1.56K | 8.14K | 8.14K | - | - | [{"date":"2020-12-31","value":19.23,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Cost of Revenue | 3.18M | 5.85M | 21.78M | 10.44M | - | [{"date":"2020-12-31","value":14.61,"profit":true},{"date":"2021-12-31","value":26.86,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":47.95,"profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Gross Profit | (3.18M) | (5.84M) | (21.78M) | (10.44M) | - | [{"date":"2020-12-31","value":-318158400,"profit":false},{"date":"2021-12-31","value":-584332930,"profit":false},{"date":"2022-12-31","value":-2178122100,"profit":false},{"date":"2023-12-31","value":-1044495700,"profit":false},{"date":"2024-12-31","value":"-","profit":true}] |
| Gross Margin | (203296.10%) | (71796.84%) | (267625.31%) | - | - | [{"date":"2020-12-31","value":-203296.1,"profit":false},{"date":"2021-12-31","value":-71796.84,"profit":false},{"date":"2022-12-31","value":-267625.31,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Operating Expenses | 2.48M | 8.26M | 23.38M | 8.45M | 16.83M | [{"date":"2020-12-31","value":10.61,"profit":true},{"date":"2021-12-31","value":35.34,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":36.15,"profit":true},{"date":"2024-12-31","value":71.97,"profit":true}] |
| Operating Income | (5.66M) | (8.25M) | (23.38M) | (18.90M) | (16.83M) | [{"date":"2020-12-31","value":-566239200,"profit":false},{"date":"2021-12-31","value":-824967295,"profit":false},{"date":"2022-12-31","value":-2337991200,"profit":false},{"date":"2023-12-31","value":-1889769300,"profit":false},{"date":"2024-12-31","value":-1682747800,"profit":false}] |
| Total Non-Operating Income/Expense | 1.22M | (1.91M) | 5.04M | 1.27M | 19.53M | [{"date":"2020-12-31","value":6.26,"profit":true},{"date":"2021-12-31","value":-9.78,"profit":false},{"date":"2022-12-31","value":25.78,"profit":true},{"date":"2023-12-31","value":6.49,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Pre-Tax Income | (5.66M) | (9.24M) | (18.06M) | (17.51M) | 2.78M | [{"date":"2020-12-31","value":-203.77,"profit":false},{"date":"2021-12-31","value":-332.6,"profit":false},{"date":"2022-12-31","value":-649.99,"profit":false},{"date":"2023-12-31","value":-629.97,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
| Income Taxes | 0.14 | 415.02K | (5.32M) | (167.90K) | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-1281.28,"profit":false},{"date":"2023-12-31","value":-40.45,"profit":false},{"date":"2024-12-31","value":"-","profit":true}] |
| Income After Taxes | (5.66M) | (9.66M) | (12.74M) | (17.34M) | - | [{"date":"2020-12-31","value":-566239214,"profit":false},{"date":"2021-12-31","value":-965755845,"profit":false},{"date":"2022-12-31","value":-1274461400,"profit":false},{"date":"2023-12-31","value":-1733824700,"profit":false},{"date":"2024-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | (4.44M) | (9.24M) | (18.06M) | (16.90M) | 2.78M | [{"date":"2020-12-31","value":-159.8,"profit":false},{"date":"2021-12-31","value":-332.6,"profit":false},{"date":"2022-12-31","value":-649.99,"profit":false},{"date":"2023-12-31","value":-608.07,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Net Income | (5.66M) | (9.66M) | (18.06M) | (17.51M) | 2.78M | [{"date":"2020-12-31","value":-203.77,"profit":false},{"date":"2021-12-31","value":-347.54,"profit":false},{"date":"2022-12-31","value":-649.99,"profit":false},{"date":"2023-12-31","value":-629.97,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
| EPS (Diluted) | (1.32) | (1.72) | (3.36) | (1.33) | 0.23 | [{"date":"2020-12-31","value":-562.76,"profit":false},{"date":"2021-12-31","value":-735.24,"profit":false},{"date":"2022-12-31","value":-1433.45,"profit":false},{"date":"2023-12-31","value":-566.6,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
| PMN | |
|---|---|
| Cash Ratio | 1.26 |
| Current Ratio | 1.76 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| PMN | |
|---|---|
| ROA (LTM) | -85.38% |
| ROE (LTM) | -355.80% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| PMN | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.57 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.43 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| PMN | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 5168.19 |
| P/B | 3.52 |
| Price/FCF | NM |
| EV/R | 3868.08 |
| EV/Ebitda | NM |
ProMIS Neurosciences Inc. (PMN) share price today is $16.29
Yes, Indians can buy shares of ProMIS Neurosciences Inc. (PMN) on Vested. To buy
Yes, you can purchase fractional shares of ProMIS Neurosciences Inc. (PMN) via the Vested app. You can start investing in ProMIS Neurosciences Inc. (PMN) with a minimum investment of $1.
You can invest in shares of ProMIS Neurosciences Inc. (PMN) via Vested in three simple steps:
The 52-week high price of ProMIS Neurosciences Inc. (PMN) is $39.75. The 52-week low price of ProMIS Neurosciences Inc. (PMN) is $6.27.
The price-to-earnings (P/E) ratio of ProMIS Neurosciences Inc. (PMN) is
The price-to-book (P/B) ratio of ProMIS Neurosciences Inc. (PMN) is 3.52
The dividend yield of ProMIS Neurosciences Inc. (PMN) is 0.00%
The market capitalization of ProMIS Neurosciences Inc. (PMN) is $34.81M
The stock symbol (or ticker) of ProMIS Neurosciences Inc. is PMN
Consider the share price of ProMIS Neurosciences Inc. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether ProMIS Neurosciences Inc. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in ProMIS Neurosciences Inc. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the ProMIS Neurosciences Inc. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of ProMIS Neurosciences Inc. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that ProMIS Neurosciences Inc. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
